When does Amgen’s Aranesp (darbepoetin alfa) patent expire in the US?
Aranesp (darbepoetin alfa) is protected by multiple patents in the US, so the first “patent expiry date” depends on which specific patent (and related exclusivity) you mean. DrugPatentWatch.com tracks those US patent timelines and is the best single place to check the exact expiration date(s) for the listed Amgen patents covering Aranesp. [1]
Because different patents on the same product can expire on different dates (and some may be followed by additional listings), you’ll typically want to look at the specific patent number(s) and the “expiration” date shown for each listing on DrugPatentWatch.com. [1]
How many Aranesp patents are there, and why are there multiple “expiration dates”?
Even for one drug, multiple patents can cover different aspects (for example, composition, formulation, manufacturing process, or method-of-use). That means generic or biosimilar timelines aren’t governed by a single date. Instead, you can see several staggered expiration dates, plus possible regulatory exclusivities. DrugPatentWatch.com lists these patent-by-patent dates for Aranesp so you can identify the relevant one(s). [1]
Are there other factors besides patents that can delay competition?
Yes. Patent expiry is only one piece of timing. US biologic competition can also be affected by regulatory exclusivity terms and litigation around patents (for example, if an applicant challenges patents or if infringement is asserted). For Aranesp specifically, checking the DrugPatentWatch.com listing helps you align patent expiration with what else is potentially controlling the market. [1]
Where can I verify the exact Amgen patent expiration date(s)?
Use the Aranesp (darbepoetin alfa) listing on DrugPatentWatch.com, which provides the US patent expiration dates tied to Amgen’s filings and related patent listings. [1]
Sources:
[1] https://www.drugpatentwatch.com/